Skip to main content
. 2016 Dec 19;40(2):153–167. doi: 10.1007/s40264-016-0486-x

Fig. 2.

Fig. 2

Reverse Kaplan–Meier curve showing time to development of a first hepatic cyst infection in autosomal dominant polycystic kidney disease patients participating in the lanreotide and control groups of the ongoing DIPAK-1 Study (interim analysis). The median time patients had received lanreotide until onset of hepatic cyst infection was 4 months (interquartile range 2–5 months)